mRNA-1273 COVID-19 vaccine effectiveness against the B.1.1.7 and B.1.351 variants and severe COVID-19 disease in Qatar
Top Cited Papers
- 9 July 2021
- journal article
- research article
- Published by Springer Science and Business Media LLC in Nature Medicine
- Vol. 27 (9), 1614-1621
- https://doi.org/10.1038/s41591-021-01446-y
Abstract
The SARS-CoV-2 pandemic continues to be a global health concern. The mRNA-1273 (Moderna) vaccine was reported to have an efficacy of 94.1% at preventing symptomatic COVID-19 due to infection with ‘wild-type’ variants in a randomized clinical trial. Here, we assess the real-world effectiveness of this vaccine against SARS-CoV-2 variants of concern, specifically B.1.1.7 (Alpha) and B.1.351 (Beta), in Qatar, a population that comprises mainly working-age adults, using a matched test-negative, case-control study design. We show that vaccine effectiveness was negligible for 2 weeks after the first dose, but increased rapidly in the third and fourth weeks immediately before administration of a second dose. Effectiveness against B.1.1.7 infection was 88.1% (95% confidence interval (CI): 83.7–91.5%) ≥14 days after the first dose but before the second dose, and was 100% (95% CI: 91.8–100.0%) ≥14 days after the second dose. Analogous effectiveness against B.1.351 infection was 61.3% after the first dose (95% CI: 56.5–65.5%) and 96.4% after the second dose (95% CI: 91.9–98.7%). Effectiveness against any severe, critical or fatal COVID-19 disease due to any SARS-CoV-2 infection (predominantly B.1.1.7 and B.1.351) was 81.6% (95% CI: 71.0–88.8%) and 95.7% (95% CI: 73.4–99.9%) after the first and second dose, respectively. The mRNA-1273 vaccine is highly effective against B.1.1.7 and B.1.351 infections, whether symptomatic or asymptomatic, and against any COVID-19 hospitalization and death, even after a single dose.Keywords
This publication has 26 references indexed in Scilit:
- Efficacy and Safety of the mRNA-1273 SARS-CoV-2 VaccineThe New England Journal of Medicine, 2021
- Emergence of SARS-CoV-2 B.1.1.7 Lineage — United States, December 29, 2020–January 12, 2021Morbidity and Mortality Weekly Report (MMWR), 2021
- Assessment of the risk of SARS-CoV-2 reinfection in an intense re-exposure settingPublished by Cold Spring Harbor Laboratory ,2020
- Molecular and Serological Tests for COVID-19. A Comparative Review of SARS-CoV-2 Coronavirus Laboratory and Point-of-Care DiagnosticsDiagnostics, 2020
- High-throughput extraction of SARS-CoV-2 RNA from nasopharyngeal swabs using solid-phase reverse immobilization beadsPublished by Cold Spring Harbor Laboratory ,2020
- Case-control vaccine effectiveness studies: Preparation, design, and enrollment of cases and controlsVaccine, 2017
- Analysis of matched case-control studiesBMJ, 2016
- Is it necessary to adjust for calendar time in a test negative design?Vaccine, 2014
- The test-negative design for estimating influenza vaccine effectivenessVaccine, 2013
- Serum Anticapsular Antibody Response in the First Week after Immunization of Adults and Infants with the Haemophilus influenzae type b-Neisseria meningitidis Outer Membrane Protein Complex Conjugate VaccineThe Journal of Infectious Diseases, 1991